Immunotherapy- (Blinatumomab-) Related Lineage Switch of KMT2A/AFF1 Rearranged B-Lymphoblastic Leukemia into Acute Myeloid Leukemia/Myeloid Sarcoma and Subsequently into B/Myeloid Mixed Phenotype Acute Leukemia

  title={Immunotherapy- (Blinatumomab-) Related Lineage Switch of KMT2A/AFF1 Rearranged B-Lymphoblastic Leukemia into Acute Myeloid Leukemia/Myeloid Sarcoma and Subsequently into B/Myeloid Mixed Phenotype Acute Leukemia},
  author={Rui R He and Zacharia Nayer and Matthew Hogan and Raymund S Cuevo and Kimberly B. Woodward and David Heyer and Christine A. Curtis and Jess F Peterson},
  journal={Case Reports in Hematology},
The presence of KMT2A/AFF1 rearrangement in B-lymphoblastic leukemia (B-ALL) is an independent poor prognostic factor and has been associated with higher rate of treatment failure and higher risk of linage switch under therapy. Blinatumomab has shown promising therapeutic results in refractory or relapsed B-ALL; however, it has potential risk of inducing lineage switch, especially in KMT2A/AFF1 rearranged B-ALL into acute myeloid leukemia and/or myeloid sarcoma. We report a 40-year-old female… 

Figures and Tables from this paper

Lineage Switch in an Infant B-Lymphoblastic Leukemia With t(1;11)(p32;q23); KMT2A/EPS15, Following Blinatumomab Therapy
  • Jing Du, Karen M. Chisholm, Min Xu
  • Medicine, Biology
    Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • 2021
A 6 month-old infant girl with t(1;11)(p32;q23), KMT2A/EPS15-rearranged B-acute lymphoblastic leukemia (B-ALL) that was refractory to traditional ALL-directed chemotherapy experienced lineage switch from B-ALL to acute myeloid leukemia (AML) and relapsed one-month post-transplantation.
To B- or not to B-: A review of lineage switched acute leukemia.
Transformation from B-lineage to myeloid lineage is the most common switch observed, and is frequently associated with a balanced 11q23 translocation, involving KMT2A.
Bispecific antibodies in acute lymphoblastic leukemia therapy
This review discusses the main structural and functional features of blinatumomab, and its place in the treatment of ALL, as well as the prospects to increase the efficacy and developments in the field of bispecific antibodies.
Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy
A number of important clinical considerations and questions remain, including the potential role of blinatumomab in the frontline setting, mechanisms of resistance, optimal goal MRD level, the role of transplant following MRD clearance, the optimal place for bl in the context of other recently approved immune-mediated therapies, and real world outcomes for patients treated outside the contexts of clinical trials.
Mixed Phenotype/Lineage Leukemia: Has Anything Changed for 2021 on Diagnosis, Classification, and Treatment?
Genomic and immunophenotypic aspects more clearly link MPAL subtypes with bona fide acute myeloblastic of lymphoblastic leukemias, likely to impact therapeutic strategies, towards a better management and outcome.
LAMP-5 is an essential inflammatory-signaling regulator and novel immunotherapy target for mixed lineage leukemia-rearranged acute leukemia
It is postulate that LAMP-5 could potentially serve as an immunotherapeutic target with a wide therapeutic window to treat MLL-r leukemias, based on the limited expression throughout human tissues.
When Flow Is Turbulent: CD19 Intensity Is a Pitfall in Acute Leukemia Classification
Cases of an MPAL, initially classified as an acute myeloid leukemia with weak CD19 expression and later reclassified upon clear demonstration of a B-cell component highlight a pitfall in classification of acute leukemias, particularly given heterogeneous antigen expression between fluorochromes and subjectivity in judgment of intensity.
The landscape of bispecific T cell engager in cancer treatment
The landscape of BiTE therapy is depicted, including clinical advances with potential response predictors, challenges of treatment toxicity and resistance, and developments of novel immune cell-based engager therapy.
Cancer immunotherapy: Challenges and limitations.


Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.
Administration of lymphodepletion chemotherapy followed by CD19-specific chimeric antigen receptor (CAR)-modified T cells is a remarkably effective approach to treating patients with relapsed and
Lineage Switch in MLL‐Rearranged Infant Leukemia Following CD19‐Directed Therapy
An infant with ALL with t(4;11)(q21;q23) refractory to cytotoxic chemotherapy who was treated with blinatumomab is reported, and bone marrow evaluation demonstrated a leukemic lineage switch to CD19‐negative monoblastic AML.
MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches
The normal biological roles of MLL1 and its fusion partners are discussed, how these roles are hypothesized to be dysregulated in the context of M LL1 rearrangements, and the clinical manifestations of this group of leukemias are discussed.
Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy
The persistence of the translocation t(4;11)(q21;q23) associated with cytogenetic evolution suggests that the monocytic leukemia results from an evolution of the original clone, rather than the essential transformation event targets an early hematopoietic progenitor that is still able to differentiate whatever the lineage.
Lineage switch in childhood acute leukemia: An unusual event with poor outcome
The association of lineage switches with MLL gene alterations and the involvement of a common lymphoid B‐myeloid precursor is supported, and new therapies should be designed to address these rare cases.
The MLL recombinome of acute leukemias in 2017
This study provides a comprehensive analysis of the MLL recombinome in acute leukemia and demonstrates that the establishment of patient-specific chromosomal fusion sites allows the design of specific PCR primers for minimal residual disease analyses for all patients.
CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
Changes in lineage markers including myeloid conversion in patients following CD19 CAR therapy are reported, establishing lineage switch as a mechanism of CAR resistance exposing inherent plasticity in genetic subtypes of pre-B-cell ALL.
Interleukin 6 induces myeloid differentiation of a human biphenotypic leukemic cell line.
Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis
Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis
Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia.